Background: Integrase inhibitors have been associated with excess gestational weight gain
that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD …

Objectives We assessed real‐world weight change and pregnancy outcomes among
pregnant women living with HIV who used integrase strand transferase inhibitor (INSTI) …

Background No published studies have evaluated in pregnant women with HIV weight gain
with different antiretroviral drug classes. Methods Data from a national cohort study were …

Introduction Antiretrovirals such as dolutegravir (DTG) and tenofovir alafenamide (TAF) have
been associated with excessive weight gain. The objective of this study was to understand …

Background We evaluated associations between antepartum weight change and adverse
pregnancy outcomes and between antiretroviral therapy (ART) regimens and week 50 …

Objective: Integrase inhibitors, including dolutegravir (DTG), are associated with weight gain
and obesity, especially when combined with tenofovir alafenamide (TAF). Obesity increases …

Background Gestational weight gain above Institute of Medicine recommendations is
associated with increased risk of pregnancy complications. The goal was to analyze the …

Background Recent data suggests clinically significant weight gain among non-pregnant
HIV-positive adults after starting dolutegravir-based ART (DTG). Excess or insufficient weight …

Introduction: Integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy
(ART) has been associated with weight gain, though there is limited information on …

Introduction Outside of pregnancy, evidence shows that persons with HIV initiating or
switching to dolutegravir (DTG)‐based antiretroviral therapy (ART) experience greater …